Jaguar Health regains Nasdaq equity compliance after $27M in capital events

Jaguar Health, Inc.

Stockholders' deficit was $18.7M at Dec 31, 2025, below Nasdaq's $2.5M minimum.
Received $16M license fee, $3M buy-back termination, $1M inventory purchase from Woodward/Future Pak.
Also received $2M MSA condition payment, $1.2M firm order, grant revenue, and $0.2M net sales.
Gain of $3.4M on debt extinguishment to Chicago Venture Partners helped restore equity.
Company believes stockholders' equity exceeded $2.5M as of April 7, 2026, curing the deficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.